Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/14598
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLimenta L.M.G.
dc.contributor.authorJirasomprasert T.
dc.contributor.authorJittangprasert P.
dc.contributor.authorWilairat P.
dc.contributor.authorYamanont P.
dc.contributor.authorChantharaksri U.
dc.contributor.authorFucharoen S.
dc.contributor.authorMorales N.P.
dc.date.accessioned2021-04-05T03:35:53Z-
dc.date.available2021-04-05T03:35:53Z-
dc.date.issued2011
dc.identifier.issn3125963
dc.identifier.other2-s2.0-78649929842
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-78649929842&doi=10.2165%2f11536630-000000000-00000&partnerID=40&md5=aa97fef21fc9b8a3faf03a1d169c3fea
dc.identifier.urihttp://ir.swu.ac.th/jspui/handle/123456789/14598-
dc.description.abstractBackground and Objective: Iron-rich transfusions and/or a compensatory increase in iron absorption ultimately result in iron loading in patients with b-thalassaemia. Hence, without iron chelation, iron accumulates relentlessly. Deferiprone has been shown to be capable of reducing the iron burden in patients with b-thalassaemia. However, there is wide interpatient variation in deferiprone-induced urinary iron excretion (UIE). We hypothesized that splenectomy and iron status might influence the pharmacokinetic profiles of deferiprone in patients with b-thalassaemia/haemoglobin E, and the present study was aimed at examining this hypothesis. Study Participants and Methods: Thirty-one patients with b-thalassaemia/haemoglobin E (20 splenectomized and 11 non-splenectomized patients) were enrolled in the study. After an overnight fast, the subjects received a single oral dose of deferiprone 25mg/kg of bodyweight. Blood samples were collected pre-dosing and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 and 480 minutes after dosing. Urine output was pooled and collected at 0-2, 2-4, 4-8, 8-12 and 12-24 hour intervals. Serum and urine concentrations of deferiprone and its metabolite deferiprone glucuronide were determined using a validated high-performance liquid chromatography method. Serum deferiprone-chelated iron and UIE were determined using a validated colourimetric method. Results: No significant difference in the pharmacokinetic parameters of non-conjugated deferiprone was observed between splenectomized and non-splenectomized patients. However, the maximum serum concentration (C max) and the area under the serum concentration-time curve (AUC) from time zero to infinity (AUC 1 ) values of deferiprone glucuronide were significantly lower (both p < 0.05) in splenectomized patients (median 53.2 μmol/L and 12 634 μmol • min/L, respectively) than in non-splenectomized patients (median 70.5 μmol/L and 20 601 mmol • min/L, respectively). The Cmax and the AUCfrom time zero to the time of the last measurable concentration (AUClast) values of serum deferiprone-chelated iron, as well as UIE, were significantly higher (p < 0.001) in splenectomized patients (median values 7.1 μmol/L, 1645 μmol • min/L and 77.1 μmol, respectively) than in non-splenectomized patients (median values 3.1 μmol/L, 545 μmol • min/L and 12.5 μmol, respectively). Urinary excretion of non-conjugated deferiprone and deferiprone glucuronide did not differ between the two groups. Further analyses using multiple linear regressions indicated that the iron profiles (non-transferrin-bound iron and ferritin) were significant predictors of the pharmacokinetic parameters of non-conjugated deferiprone, deferiprone-chelated iron and UIE. In addition, splenectomy status was identified as the strongest predictor of the AUClast of deferiprone-chelated iron and UIE. Conclusion: Both iron and splenectomy status have significant effects on the pharmacokinetics and iron chelation efficacy of deferiprone. A greater degree of iron overload in splenectomized patients results in alterations in pharmacokinetic parameters (theCmax and AUC) of deferiprone glucuronide and deferipronechelated iron, as well as a significant increase in UIE. © 2011 Adis Data Information BV. All rights reserved.
dc.subjectdeferiprone
dc.subjectdeferiprone glucuronide
dc.subjectdrug metabolite
dc.subjectferritin
dc.subjectgpo l1
dc.subjecthemoglobin E
dc.subjectiron
dc.subjectiron chelate
dc.subjecttransferrin
dc.subjectunclassified drug
dc.subjectadult
dc.subjectarea under the curve
dc.subjectarticle
dc.subjectbeta thalassemia
dc.subjectblood sampling
dc.subjectdiet restriction
dc.subjectdrug activity
dc.subjectdrug blood level
dc.subjectdrug conjugation
dc.subjectdrug efficacy
dc.subjectdrug urine level
dc.subjectfemale
dc.subjectglucuronidation
dc.subjecthigh performance liquid chromatography
dc.subjecthuman
dc.subjectiron binding capacity
dc.subjectiron blood level
dc.subjectiron chelation
dc.subjectiron metabolism
dc.subjectiron overload
dc.subjectmaximum plasma concentration
dc.subjectmultiple linear regression analysis
dc.subjectplasma concentration-time curve
dc.subjectpriority journal
dc.subjectsingle drug dose
dc.subjectsplenectomy
dc.subjecturinary excretion
dc.subjecturine volume
dc.subjectAdministration, Oral
dc.subjectAdult
dc.subjectArea Under Curve
dc.subjectbeta-Thalassemia
dc.subjectBlood Transfusion
dc.subjectFemale
dc.subjectFerritins
dc.subjectHemoglobin E
dc.subjectHumans
dc.subjectIron
dc.subjectIron Chelating Agents
dc.subjectIron Overload
dc.subjectMale
dc.subjectPyridones
dc.subjectSplenectomy
dc.subjectTransferrin
dc.titlePharmacokinetics of deferiprone in patients with β-thalassaemia: Impact of splenectomy and iron status
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationClinical Pharmacokinetics. Vol 50, No.1 (2011), p.41-50
dc.identifier.doi10.2165/11536630-000000000-00000
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.